Get started
Author

Henrik Loft

Memantine for Agitation/Aggression and Psychosis in Moderately Severe to Severe Alzheimer's Disease: A Pooled Analysis of 3 Studies
2008 · Gordon K. Wilcock, Clive G. Ballard, et al. · The Journal of Clinical Psychiatry · 256
Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care
2003 · Ulla M. Lepola, Henrik Loft, et al. · International Clinical Psychopharmacology · 253
A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder
2011 · Enric Alvarez, Victor Perez, et al. · The International Journal of Neuropsychopharmacology · 229
PDF
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis
2007 · S. Gauthier, H. Loft, et al. · International Journal of Geriatric Psychiatry · 226
The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials
2016 · RS McIntyre, J Harrison, et al. · The International Journal of Neuropsychopharmacology · 195
PDF
Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: a randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder
2013 · Jean-Philippe Boulenger, Henrik Loft, et al. · International Clinical Psychopharmacology · 185
Escitalopram (S-Enantiomer of Citalopram): Clinical Efficacy and Onset of Action Predicted from a Rat Model
2001 · Stuart A. Montgomery, Henrik Loft, et al. · Pharmacology & Toxicology · 177
PDF
Oral clodronate in breast cancer patients with bone metastases: a randomized study
1999 · B. Kristensen, B. Ejlertsen, et al. · Journal of Internal Medicine · 175
PDF
A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults
2016 · Michael E. Thase, Atul R. Mahableshwarkar, et al. · European Neuropsychopharmacology · 165
PDF
A randomised, double-blind, placebo controlled, duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD)
2011 · David S. Baldwin, Henrik Loft, et al. · European Neuropsychopharmacology · 164
Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study
2007 · S. Bakchine, H. Loft · Journal of Alzheimer s Disease · 135
Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment
2020 · Andrea Fagiolini, Ioana Florea, et al. · Journal of Affective Disorders · 132
PDF
A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder
2012 · Jean-Philippe Boulenger, Henrik Loft, et al. · Journal of Psychopharmacology · 130
Escitalopram in the treatment of social anxiety disorder: Randomised, placebo-controlled, flexible-dosage study
2005 · Siegfried Kasper, Dan J. Stein, et al. · The British Journal of Psychiatry · 128
PDF
A 24-Week Randomized, Double-Blind, Placebo-Controlled Study of Escitalopram for the Prevention of Generalized Social Anxiety Disorder
2005 · Stuart A. Montgomery, Rico Nil, et al. · The Journal of Clinical Psychiatry · 115
Efficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
2016 · Roger S. McIntyre, Ioana Florea, et al. · The Journal of Clinical Psychiatry · 102
Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study
2008 · S. Bakchine, H. Loft · Journal of Alzheimer s Disease · 98
PDF
Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder
2021 · Roger S McIntyre, Henrik Loft, et al. · Neuropsychiatric Disease and Treatment · 87
PDF
Factors associated with failure to achieve remission and with relapse after remission in patients with major depressive disorder in the PERFORM study
2017 · Delphine Saragoussi, Maëlys Touya, et al. · Neuropsychiatric Disease and Treatment · 75
PDF
Monoacylglycerol Lipase Inhibition in Tourette Syndrome: A 12‐Week, Randomized, Controlled Study
2021 · Kirsten R. Müller‐Vahl, Carolin Fremer, et al. · Movement Disorders · 60
PDF
PET measurement of serotonin transporter occupancy: a comparison of escitalopram and citalopram
2007 · Johan Lundberg, Jacob Strøyer Christophersen, et al. · The International Journal of Neuropsychopharmacology · 56
PDF
Lu 25-109, a muscarinic agonist, fails to improve cognition in Alzheimer’s disease
2000 · L.J. Thal, M. Forrest, et al. · Neurology · 55
Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting
2021 · Michael Cronquist Christensen, Andrea Fagiolini, et al. · Journal of Affective Disorders · 54
PDF
Effect of Short-term Treatment With Gaboxadol on Sleep Maintenance and Initiation in Patients With Primary Insomnia
2007 · Steve Deacon, Luc Staner, et al. · SLEEP · 49
Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders
2017 · Michael Cronquist Christensen, Henrik Loft, et al. · Journal of Affective Disorders · 48
PDF
Works count: 71
Citation count: 3,952
H-index: 32
I10-index: 45
Year
Topic
Type